WHO

WHO Pipeline Review: “The world is running out of antibiotics”

Dear All:  Released just a few hours ago in parallel with the UN General Assembly meetings, WHO has produced a detailed review of the global pipeline. As they note on their overview webpage, “The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including

Read More »

Estimating attributable mortality of resistant bloodstream infections: GLASS (WHO) recommended method

Dear All, WHO’s GLASS Secretariat (Global Antimicrobial Resistance Surveillance System, link) have recently released a standardized method for estimating attributable mortality of antimicrobial resistant bloodstream infections. The webpage discussing the document is here; the document itself is here. GLASS currently collects surveillance data on infections in the blood as well as the urinary, gastrointestinal, and

Read More »

WHO Collaborating Centres for AMR: A rapidly growing group!

Dear All, I recently learned about the designation of Stanford as a WHO Collaborating Centre (WHOCC) for AMR and Stewardship. This caused me to dig a bit more into the way that WHO has created a global network of Collaborating Centres. WHOCC designation represents a sustained and productive collaboration with WHO (link). As an example, Stanford’s

Read More »

WHO wants your input on its draft TPPs for needed antibacterial agents

Dear All, WHO has developed a set of draft TPPs (target product profiles) for needed new antibiotics. As part of the process, they are now opening a public consultation. Here is the essential text from their announcement: “The World Health organization (WHO) is developing target products profiles (TPPs) for needed antibacterial agents, providing the public

Read More »

Two things: WHO’s looking GLASS + FDA’s advances with PDUFA VI

Dear All: Two things today. Unrelated, but both relevant! WHO’s GLASS: WHO’s Global Antimicrobial Resistance Surveillance System (GLASS) was created during October 2015 and seeks to obtain coordinated and consistent global estimates on resistance rates. In a major report released on 29 Jan 2018, GLASS now provides provides official national AMR data for the period 2016-17 from 40 countries

Read More »

WHO wants to hear from all pre-clinical antibiotic developers (18 Mar 2019 deadline)

​Dear All: Are you doing preclinical antibiotic R&D? If so, WHO wants to hear from you! As you know, WHO has published these two analyses of priority pathogens and antibacterial agents currently in Phases 1-3: Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis (2017, link) 

Read More »

Short-term WHO role to support analysis of pre-clinical pipeline

Dear All: I wrote previously (link to newsletter) about WHO’s call for information about pre-clinical antibiotic R&D. With a due date of 18 Mar, this is your chance to help construct a survey that can be used to drive further initiatives. In support of this, WHO is now look for a contractor to work with

Read More »

WHO 2019 Review of the Preclinical and Clinical Antibacterial Pipeline

(15 Apr 2021 update: WHO have today released a 2020 update to the report discussed in this newsletter.) Dear All, WHO has today released two exhaustive reviews of the antibacterial R&D universe (and by way of full disclosure, let me say upfront that I participated in the clinical pipeline discussion). Based on a cut-off date

Read More »
Scroll to Top